retatrutide: How Does Retatrutide Make You Lose Weight? The Science of the "Triple G" Agonist Retatrutide: The Triple Agonist That

S., Helmby, H

Kaisers 2026 PA criteria for Wegovy vary by region but generally require BMI of 35 or higher, or BMI 30 to 34.9 with at least one severe weight-related comorbidity (type 2 diabetes, severe OSA, severe hypertension, dyslipidemia with documented CVD risk), documentation of a structured weight management program through Kaiser for at least 12 months, prescriber attestation of inadequate response to lifestyle modification, and age 18 or older

Expert Rev Anticancer Ther

Observing for any adverse effects while undergoing treatment is vital

2,3 This project will extend the literature through an exploration of weight trajectories after cessation of long-term GLP-1 RA therapy and specifically seeks to answer the question: is there a duration of treatment with GLP-1 RA therapy after which weight loss is durable